Clinic
Inova Health Care Services
Inova Health Care Services was paid $46.97M by Medicaid between Jan 2018 and Dec 2024, across 300 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoINOVA HEALTH CARE SERVICES
LEESBURG, VA 20176
LEESBURG, VA 20176
33aNPI1376564302assigned 07/23/2006
33bProvider typeSubstance Use Disorder Rehabilitation Clinic/Center
28Total paid$46.97M
24GClaims957,277
24DCodes billed300
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Substance Use Disorder Rehabilitation Clinic/Center providers in Virginia
Rank by total paid#3 of 22
Median peer was paid$2.19M
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,989 | $2.96M | |
| 2019 | 110,698 | $4.27M | |
| 2020 | 98,102 | $4.14M | |
| 2021 | 126,663 | $5.48M | |
| 2022 | 162,777 | $8.07M | |
| 2023 | 191,112 | $10.80M | |
| 2024incomplete | 176,936 | $11.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 47,859 | 41,792 | $9.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 34,150 | 29,401 | $7.40M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 20,171 | 15,719 | $6.24M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.1% | 14,722 | 13,093 | $3.33M |
| G0378 | Hospital observation service, per hour | 4.8% | 7,617 | 6,447 | $2.28M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.1% | 14,490 | 4,439 | $1.45M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 8,155 | 7,213 | $1.44M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.6% | 28,753 | 8,736 | $1.23M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 6,794 | 6,167 | $1.14M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 6,446 | 5,837 | $860K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 5,103 | 4,592 | $813K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 1,805 | 1,673 | $603K |
288 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 2,542 | $575K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 1,740 | $572K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 5,643 | $500K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 12,195 | $488K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 6,610 | $479K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 3,515 | $475K |
| 59025 | Fetal non-stress test | <1% | 2,033 | $415K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,372 | $399K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,082 | $361K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,087 | $335K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,390 | $322K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,771 | $307K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 8,642 | $303K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,959 | $294K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,046 | $287K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,393 | $269K |
| 97161 | <1% | 2,124 | $214K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,322 | $212K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,513 | $188K |
| 80053 | Comprehensive metabolic panel | <1% | 44,124 | $181K |
| 87400 | <1% | 13,518 | $156K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,611 | $154K |
| 92526 | <1% | 3,729 | $150K | |
| 93976 | <1% | 2,015 | $141K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,046 | $131K |
| 76801 | <1% | 2,390 | $116K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 242 | $99K |
| 97162 | <1% | 627 | $99K | |
| 76770 | <1% | 714 | $96K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 429 | $93K |
| 93971 | <1% | 1,012 | $90K | |
| 70496 | <1% | 378 | $88K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,759 | $85K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 370 | $82K |
| 97165 | <1% | 941 | $81K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,143 | $76K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,191 | $72K |
| 93970 | <1% | 572 | $70K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 503 | $68K |
| 87420 | <1% | 3,863 | $63K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 379 | $60K |
| 12001 | <1% | 284 | $56K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 11,428 | $55K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,367 | $54K |
| 92610 | <1% | 426 | $47K | |
| 87040 | <1% | 7,274 | $43K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,592 | $42K |
| 87505 | <1% | 491 | $40K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 43 | $37K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,022 | $36K |
| 92523 | <1% | 291 | $36K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,648 | $34K |
| J3490 | Unclassified drugs | <1% | 15,339 | $34K |
| 12011 | <1% | 161 | $34K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,930 | $33K |
| 72131 | <1% | 651 | $31K | |
| 83880 | <1% | 4,207 | $30K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 47,590 | $30K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,170 | $29K |
| 74018 | <1% | 1,979 | $28K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,277 | $28K |
| 70486 | <1% | 596 | $27K | |
| 71250 | <1% | 463 | $26K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,484 | $26K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 165 | $25K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,668 | $24K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,913 | $22K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,839 | $22K |
| 73564 | <1% | 1,662 | $21K | |
| 85379 | <1% | 4,693 | $21K | |
| 87081 | <1% | 16,394 | $20K | |
| 70498 | <1% | 428 | $20K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,071 | $19K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 71 | $19K |
| 84484 | <1% | 16,149 | $19K | |
| 73630 | <1% | 1,968 | $17K | |
| 76536 | <1% | 142 | $16K | |
| 85027 | <1% | 6,988 | $16K | |
| 73610 | <1% | 1,931 | $16K | |
| 76820 | <1% | 627 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 829 | $15K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 85 | $15K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,351 | $14K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 264 | $14K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 635 | $13K |
| 90715 | <1% | 593 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,127 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,913 | $12K |
| 73030 | <1% | 1,409 | $12K | |
| 96376 | <1% | 6,444 | $12K | |
| 76870 | <1% | 164 | $12K | |
| 73080 | <1% | 620 | $11K | |
| 70491 | <1% | 62 | $11K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 801 | $9K |
| 87430 | <1% | 15,755 | $9K | |
| 80143 | <1% | 2,403 | $9K | |
| 73560 | <1% | 644 | $8K | |
| 86780 | <1% | 1,347 | $8K | |
| 73130 | <1% | 1,128 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,334 | $7K |
| 73590 | <1% | 641 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,551 | $6K |
| 73110 | <1% | 798 | $6K | |
| 82728 | <1% | 683 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 398 | $6K |
| 86140 | <1% | 3,796 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,939 | $6K |
| 80061 | Lipid panel | <1% | 1,783 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $6K |
| 93798 | <1% | 65 | $6K | |
| 97163 | <1% | 35 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,991 | $6K |
| 81003 | <1% | 8,576 | $6K | |
| 84702 | <1% | 3,094 | $5K | |
| 74019 | <1% | 1,365 | $5K | |
| 76642 | <1% | 57 | $5K | |
| 81001 | <1% | 20,155 | $5K | |
| 74183 | <1% | 13 | $5K | |
| 82950 | <1% | 1,076 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,244 | $5K |
| 73090 | <1% | 360 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 256 | $5K |
| 86900 | <1% | 4,840 | $5K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 20 | $5K |
| 83735 | <1% | 13,285 | $5K | |
| 80179 | <1% | 2,310 | $5K | |
| 83690 | <1% | 13,784 | $5K | |
| 82248 | <1% | 1,826 | $4K | |
| 96367 | <1% | 472 | $4K | |
| 97116 | <1% | 281 | $4K | |
| 83605 | <1% | 3,722 | $4K | |
| 86762 | <1% | 807 | $4K | |
| 85610 | <1% | 8,966 | $4K | |
| 86850 | <1% | 4,306 | $4K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 471 | $4K |
| 84703 | <1% | 10,663 | $4K | |
| 74174 | <1% | 15 | $4K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,761 | $3K |
| 29125 | <1% | 14 | $3K | |
| 97113 | <1% | 78 | $3K | |
| 72141 | <1% | 18 | $3K | |
| 84439 | <1% | 520 | $3K | |
| 12002 | <1% | 14 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 952 | $3K |
| 86803 | <1% | 853 | $3K | |
| 85014 | <1% | 1,235 | $3K | |
| 82247 | <1% | 631 | $3K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 9,428 | $2K |
| 93017 | <1% | 55 | $2K | |
| 83550 | <1% | 610 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,040 | $2K |
| 85652 | <1% | 4,531 | $2K | |
| 87077 | <1% | 3,938 | $2K | |
| 86901 | <1% | 4,835 | $2K | |
| 72128 | <1% | 77 | $2K | |
| 87340 | <1% | 1,109 | $2K | |
| 84100 | <1% | 4,126 | $2K | |
| 73140 | <1% | 308 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 344 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,657 | $2K |
| 83540 | <1% | 635 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,473 | $2K |
| 85730 | <1% | 7,603 | $2K | |
| 81025 | <1% | 4,054 | $2K | |
| 82105 | <1% | 77 | $2K | |
| 82550 | <1% | 2,219 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 121 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $1K |
| 82570 | <1% | 797 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,954 | $1K |
| 87186 | <1% | 3,203 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 68 | $997.81 |
| 73502 | <1% | 61 | $937.02 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 760 | $870.78 |
| 85018 | <1% | 562 | $858.87 | |
| 72100 | <1% | 39 | $840.94 | |
| 84156 | <1% | 668 | $723.86 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,550 | $722.51 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 49 | $653.05 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,459 | $635.14 |
| 87205 | <1% | 1,444 | $632.38 | |
| 82607 | <1% | 73 | $627.20 | |
| 87070 | <1% | 1,450 | $621.73 | |
| 72110 | <1% | 14 | $602.39 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,847 | $509.61 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,424 | $509.14 |
| 88304 | <1% | 221 | $467.95 | |
| 84550 | <1% | 780 | $447.11 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 927 | $442.40 |
| 87210 | <1% | 964 | $427.84 | |
| 86141 | <1% | 2,097 | $377.24 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 895 | $327.69 |
| 83615 | <1% | 689 | $317.36 | |
| 36416 | <1% | 416 | $317.23 | |
| 87563 | <1% | 180 | $303.34 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,057 | $295.23 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 12 | $282.45 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 15 | $274.90 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,523 | $271.81 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 387 | $264.40 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,471 | $253.77 |
| 87486 | <1% | 12 | $247.34 | |
| 85049 | <1% | 102 | $238.19 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,268 | $231.66 |
| C1769 | Guide wire | <1% | 517 | $225.20 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,845 | $210.43 |
| 82565 | <1% | 180 | $190.92 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 14 | $188.30 |
| 90686 | <1% | 15 | $184.59 | |
| 82951 | <1% | 13 | $177.46 | |
| 83655 | <1% | 16 | $172.72 | |
| 84450 | <1% | 193 | $171.88 | |
| 87581 | <1% | 12 | $154.86 | |
| 73501 | <1% | 13 | $154.68 | |
| 86038 | <1% | 15 | $151.27 | |
| 86308 | <1% | 506 | $149.81 | |
| 72170 | <1% | 64 | $146.49 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,653 | $136.32 |
| 73552 | <1% | 47 | $134.82 | |
| 88342 | <1% | 57 | $134.08 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,006 | $132.68 |
| 99152 | <1% | 180 | $114.13 | |
| 80076 | <1% | 13 | $103.08 | |
| 86665 | <1% | 186 | $101.08 | |
| 84145 | <1% | 679 | $100.87 | |
| 82746 | <1% | 13 | $99.64 | |
| 84460 | <1% | 199 | $99.29 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 994 | $98.28 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,061 | $95.94 |
| 86664 | <1% | 99 | $91.17 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 854 | $88.49 |
| 87328 | <1% | 182 | $83.38 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 803 | $82.83 |
| 86317 | <1% | 12 | $72.49 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 221 | $69.87 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,081 | $55.42 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $48.64 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 276 | $48.45 |
| 84112 | <1% | 74 | $42.03 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 188 | $40.17 |
| 94664 | <1% | 203 | $38.30 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 230 | $21.98 |
| 85007 | <1% | 153 | $21.24 | |
| 87425 | <1% | 86 | $19.62 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 191 | $17.52 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 204 | $14.51 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 582 | $14.18 |
| 82805 | <1% | 89 | $14.12 | |
| 87329 | <1% | 50 | $10.12 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 21 | $7.04 |
| 86618 | <1% | 37 | $6.16 | |
| J1815 | Injection, insulin, per 5 units | <1% | 88 | $5.78 |
| 87075 | <1% | 17 | $5.23 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 492 | $4.24 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 305 | $2.85 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 96 | $1.25 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 455 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 306 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 273 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 16 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 220 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 254 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 127 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,489 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 24 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 76 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 102 | $0.00 |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | 0% | 16 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 57 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 21 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 104 | $0.00 |
| J7699 | Noc drugs, inhalation solution administered through dme | 0% | 31 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 133 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 365 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 123 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 115 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 84 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 67 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 24 | $0.00 |
| 99292 | 0% | 55 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 39 | $0.00 |
| 73060 | 0% | 25 | $0.00 | |
| 94760 | 0% | 14 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 64 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 12 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 33 | $0.00 |
| 80047 | 0% | 47 | $0.00 | |
| 87493 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTALENTO, RICARDO (CORPORATE CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Inova Health Care Services | Falls Church, VA | $176.68M |
| Inova Health Care Services | Alexandria, VA | $69.02M |
| Inova Health Care Services | Alexandria, VA | $39.33M |
| Inova Health Care Services | Fairfax, VA | $33.53M |
| Inova Health Care Services | Springfield, VA | $8.88M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.